<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tobramycin (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tobramycin (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tobramycin (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="104955" href="/d/html/104955.html" rel="external">see "Tobramycin (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="104958" href="/d/html/104958.html" rel="external">see "Tobramycin (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F45031119"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Nephrotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tobramycin can result in acute kidney injury, including acute renal failure. Risk factors that may contribute to nephrotoxicity include tobramycin accumulation (increasing serum trough levels), high peak concentrations (&gt;12 mcg/mL), total cumulative dose, advanced age, volume depletion, and concurrent or sequential use of other nephrotoxic drugs. Avoid concurrent or sequential use of other potentially nephrotoxic drugs. Monitor serum tobramycin levels and renal function in all patients during drug treatment. Reduce the dose or discontinue tobramycin if renal impairment occurs.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ototoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tobramycin can cause irreversible auditory and vestibular toxicity that may continue to develop after the drug has been discontinued. Risk factors include high serum concentrations, prolonged therapy, renal impairment, concurrent and sequential use of other nephrotoxic or ototoxic drugs (eg, aminoglycosides), and extremes of age. Avoid concurrent or sequential use with other potentially ototoxic drugs. Monitor for signs and symptoms of auditory and vestibular toxicity. Reduce the dose or discontinue tobramycin if renal impairment occurs. Discontinue tobramycin if ototoxicity occurs.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuromuscular blockade:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides have been associated with neuromuscular blockade. During therapy with tobramycin, monitor for adverse reactions associated with neuromuscular blockade, particularly in high-risk patients, such as patients with underlying neuromuscular disorders (including myasthenia gravis) or in patients concomitantly receiving neuromuscular-blocking agents<b>. </b></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Embryo-fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tobramycin and other aminoglycosides can cause fetal harm when administered to a pregnant woman. If tobramycin is used during pregnancy or if the patient becomes pregnant while taking tobramycin, apprise the patient of the potential hazard to the fetus.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872035"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP-Tobramycin [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F45503721"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Aminoglycoside</span></li></ul></div>
<div class="block don drugH1Div" id="F53462696"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Determination of dosing interval requires consideration of multiple factors including concomitant medications (eg, ibuprofen, indomethacin), history of birth depression, birth hypoxia/asphyxia, and presence of cyanotic congenital heart disease. Dosage should be individualized based upon serum concentration monitoring. Impact of extracorporeal membrane oxygenation (ECMO) on neonatal pharmacokinetic parameters is not fully elucidated; optimal dose and frequency not established in ECMO patients; available data is very limited and based on gentamicin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12739981','lexi-content-ref-2764529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12739981','lexi-content-ref-2764529'])">Ref</a></span>). Patient-specific considerations (eg, reason for ECMO) and variability with ECMO procedure itself make extrapolation of pharmacokinetic data and dosing to all patients receiving ECMO difficult; closely monitor serum concentrations and determine individual dosing needs in these patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing; susceptible infection:</b> Limited data available: Dosing strategies may vary by institution as a wide variety of extended-interval dosing regimens have been studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31492162','lexi-content-ref-12011820','lexi-content-ref-26986995','lexi-content-ref-32507958','lexi-content-ref-11144309','lexi-content-ref-25766737','lexi-content-ref-29358294','lexi-content-ref-26836810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31492162','lexi-content-ref-12011820','lexi-content-ref-26986995','lexi-content-ref-32507958','lexi-content-ref-11144309','lexi-content-ref-25766737','lexi-content-ref-29358294','lexi-content-ref-26836810'])">Ref</a></span>). Due to maturational processes and developing pharmacokinetics, regimens referred to as "extended-interval" in neonates do not typically achieve concentrations that would be expected with extended-interval dosing in children and adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31492162','lexi-content-ref-25465576','lexi-content-ref-29358294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31492162','lexi-content-ref-25465576','lexi-content-ref-29358294'])">Ref</a></span>). Some dosing is based on gentamicin studies.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Age-directed dosing </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>): IM, IV: <b>Note:</b> Higher doses and different dosing intervals may be required to achieve target concentrations if MIC ≥1 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-29358294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-29358294'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Gestational</b>
<b>Age</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Postnatal</b>
<b>Age</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Dose</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">&lt;30 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">≤14 days</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg/kg/dose every 48 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥15 days</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg/kg/dose every 36 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">30 to 34 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">≤10 days</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg/kg/dose every 36 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">11 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">≥35 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">≤7 days</p></td>
<td align="center">
<p style="text-indent:0em;">4 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg/kg/dose every 24 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment in renal impairment:</b> Consider single-dose administration with serum concentration monitoring rather than scheduled dosing in patients with urine output &lt;1 mL/kg/hour or if SCr significantly increases from baseline.</p></div>
<div class="block dop drugH1Div" id="F45031166"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Initial dosing recommendations presented. Monitoring of serum concentrations is recommended to ensure efficacy and avoid toxicity, particularly in critically ill patients with serious infection or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, major surgery). Timing and frequency of concentration monitoring is individualized based on dosing and monitoring strategy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10073735','lexi-content-ref-21407038','lexi-content-ref-12523459','lexi-content-ref-27453702','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10073735','lexi-content-ref-21407038','lexi-content-ref-12523459','lexi-content-ref-27453702','lexi-content-ref-Manu.1'])">Ref</a></span>). Routes of administration may vary (including IM, IV, intraperitoneal, intrathecal, and intraventricular); use caution. Some dosing is based on gentamicin studies.</p>
<p style="text-indent:0em;margin-top:2em;">
<i>Dosing consideration for obesity: </i>In obese pediatric patients, use adjusted body weight (IBW + 0.4 [TBW – IBW]) to calculate initial dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2762224','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2762224','lexi-content-ref-Manu.1'])">Ref</a></span>). Alternatively, adjusted body weight for obese pediatric patients may be calculated using the equation 0.7 x TBW (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>), or fat-free mass can be used to calculate the initial dose in pediatric patients ≥2 years regardless of body habitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29521784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29521784'])">Ref</a></span>). Dosage should then be individualized based upon serum concentration monitoring.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection: Note: </b>Optimal dose and frequency not established in patients receiving extracorporeal membrane oxygenation (ECMO); patient-specific considerations (eg, reason for ECMO) and variability with ECMO procedure itself make extrapolation of pharmacokinetic data and dosing to all patients receiving ECMO difficult; closely monitor serum concentrations and determine individual dosing needs in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conventional dosing:</i> Infants, Children, and Adolescents: IM, IV: 6 to 7.5 mg/kg/<b>day</b> divided every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended-interval dosing:</i> Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed: Infants, Children, and Adolescents: IV: 5 to 7.5 mg/kg/dose every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-15231982','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-15231982','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Age-directed: Based on data from 114 pediatric patients receiving extended-interval dosing of gentamicin, the following has been suggested for tobramycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20180608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20180608'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥3 months and Children &lt;2 years: IV: 9.5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to &lt;8 years: IV: 8.5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥8 years and Adolescents: IV: 7 mg/kg/dose every 24 hours.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cc30ca9c-db9e-4f82-ad38-00cf0b11a720">Cystic fibrosis, pulmonary infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, pulmonary infection:</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conventional dosing:</i> IM, IV: 3.3 mg/kg/dose every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19729669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19729669'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended-interval dosing:</i> IV: Initial: 10 to 12 mg/kg/dose every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19729669','lexi-content-ref-15708100','lexi-content-ref-19330772','lexi-content-ref-27453702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19729669','lexi-content-ref-15708100','lexi-content-ref-19330772','lexi-content-ref-27453702'])">Ref</a></span>); maximum reported dose from a survey of 28 Cystic Fibrosis (CF) Foundation-accredited centers ranged from 12 to 20 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27453702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27453702'])">Ref</a></span>). <b>Note:</b> The CF Foundation recommends extended-interval dosing as preferred over conventional dosing.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Synergy dosing (eg, gram-positive bacteria): Children and Adolescents: IV: 3 to 6 mg/kg/<b>day</b> divided every 8 hours; use in combination with other antibiotics dependent upon pathogen and source of infection (ie, valve-type) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment dosing (eg, gram-negative bacteria): Children and Adolescents: IV: 7.5 mg/kg/<b>day</b> divided every 8 hours; use in combination with other antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02b4604f-7121-4a88-88dd-a5008cafb941">Intra-abdominal infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 3 to 7.5 mg/kg/<b>day</b> divided every 8 to 24 hours; use in combination with other antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="369ce704-426c-4757-9cb0-07521a3bf378">CNS infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Meningitis, including health care-associated meningitis</i>: Limited data available: Infants, Children, and Adolescents: IV: Initial: 7.5 mg/kg/<b>day</b> divided every 8 hours in combination with additional antimicrobials; duration should be individualized based on patient characteristics, infecting organism, and response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ventriculitis (including health care-associated ventriculitis and cerebrospinal fluid [CSF] shunt infections):</i> Limited data available: Infants, Children, and Adolescents: Intraventricular, intrathecal: <b>Use a preservative-free preparation</b>: 5 to 20 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>). Due to the smaller CSF volume in infants, some guidelines recommend decreasing the infant dose; dosage and administration interval can also be adjusted based on CSF tobramycin concentrations, ventricle size, and daily output from ventricular drain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>). Duration is individualized according to clinical and microbiological response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1762e085-16eb-4d56-91f6-48f0c61ce809">Peritonitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>): Limited data available: Infants, Children, and Adolescents: Intraperitoneal: Continuous: Loading dose: 8 mg per liter of dialysate; maintenance dose: 4 mg per liter.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Duration of therapy for multiple-dose regimens: For uncomplicated cystitis in patients ≥3 months of age, treat for 3 to 5 days; patients &lt;2 years of age may require a longer course (eg, 7 days). For complicated urinary tract infection (UTI), including pyelonephritis, treat for a total of 6 to 10 days; while 7 to 14 days has been recommended for complicated UTI, this was not shown to improve outcomes compared to a shorter duration of 6 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21873693','lexi-content-ref-36009990','lexi-content-ref-29292282','lexi-content-ref-32364593','lexi-content-ref-37897526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21873693','lexi-content-ref-36009990','lexi-content-ref-29292282','lexi-content-ref-32364593','lexi-content-ref-37897526'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conventional dosing:</i> Infants, Children, and Adolescents: IV: 5 mg/kg/<b>day</b> divided every 8 hours until clinical improvement and able to tolerate oral intake; complete course with oral antibiotics. Duration should be individualized based upon age, severity, and degree of urinary tract involvement.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended-interval dosing:</i> Limited data available: Based on data from 90 patients (ages: 1 month to 12 years) receiving gentamicin, the following age-directed dosing has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11303823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11303823'])">Ref</a></span>): <b>Note: </b>Patients were transitioned to oral therapy once afebrile for 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;5 years: IV: 7.5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 5 to 10 years: IV: 6 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 11 to 12 years: IV: 4.5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-dose regimen:</i> Limited data available. <b>Note: </b>Recommended for treatment of uncomplicated cystitis caused by antimicrobial resistant gram-negative pathogens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33106864']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33106864'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IM: 5 mg/kg as a single dose; dosing based on 2 prospective studies evaluating single-dose IM gentamicin in patients 1 month to 15 years and a systematic review evaluating studies of various single-dose aminoglycosides in pediatric and adult patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30397061','lexi-content-ref-3794874','lexi-content-ref-Varese.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30397061','lexi-content-ref-3794874','lexi-content-ref-Varese.1'])">Ref</a></span>); one study limited doses to 300 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3794874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3794874'])">Ref</a></span>). An overall pooled cure rate for single dose IM aminoglycoside for treatment of children and adults with mainly uncomplicated cystitis was reported as 94.5% ± 4.3% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30397061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30397061'])">Ref</a></span>). <b>Note:</b> Guidelines do not address pediatric dosing; recommended aminoglycoside doses in adults include IV single doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33106864']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33106864'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192877"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: <b>Note: </b>Tobramycin serum concentrations should be monitored in patients with kidney impairment; following the initial dose, subsequent doses may be determined based on therapeutic monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IM, IV:</p>
<p style="text-indent:-2em;margin-left:6em;">The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 2.5 mg/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:8em;">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer every 12 to 18 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer every 18 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer every 48 to 72 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis: Dialyzable (25% to 70%): 2 mg/kg/dose; redose as indicated by serum concentrations.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis (PD): 2 mg/kg/dose; redose as indicated by serum concentrations.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): 2 to 2.5 mg/kg/dose every 12 to 24 hours, monitor serum concentrations.</p></div>
<div class="block dohp drugH1Div" id="F51192878"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment not likely to be necessary (does not undergo hepatic metabolism).</p></div>
<div class="block doa drugH1Div" id="F45031167"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="104955" href="/d/html/104955.html" rel="external">see "Tobramycin (systemic): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>For patients who are underweight (ie, total body weight [TBW] &lt; ideal body weight [IBW]), calculate the dose based on TBW. For patients who are nonobese (ie, TBW 1 to 1.25 × IBW), calculate the dose based on TBW or IBW. TBW may be preferred in patients who are nonobese who may have increased V<sub>d</sub> (eg, critically ill). For patients with obesity (ie, TBW &gt;1.25 × IBW), use adjusted body weight ([0.4 × (TBW − IBW)] + IBW) for initial weight-based dosing and for estimating kidney function with Cockcroft-Gault (CrCl) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9142771','lexi-content-ref-25455848','lexi-content-ref-7793867','lexi-content-ref-24268292','lexi-content-ref-19057371','lexi-content-ref-7726530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9142771','lexi-content-ref-25455848','lexi-content-ref-7793867','lexi-content-ref-24268292','lexi-content-ref-19057371','lexi-content-ref-7726530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Therapeutic drug monitoring is recommended to ensure efficacy and avoid toxicity, particularly in patients who are critically ill with serious infection or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, major surgery). Timing and frequency of concentration monitoring is individualized based on dosing and monitoring strategy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8137600','lexi-content-ref-12122533','lexi-content-ref-24756148']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8137600','lexi-content-ref-12122533','lexi-content-ref-24756148'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gram negative infections</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Conventional/traditional dosing: <b>IV, IM:</b> 3 to 5 mg/kg/day in divided doses every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Some experts favor an initial loading dose of 2.5 to 3 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drew.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drew.2020'])">Ref</a></span>). Target peak concentration depends on indication and site of infection; in general, adjust dose to achieve peak of 4 to 6 mg/L for urinary tract infections and 7 to 10 mg/L for serious infections (including life-threatening infections). Target trough concentrations should be &lt;2 mg/L; ideal target &lt;1 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8137600','lexi-content-ref-Drew.2020','lexi-content-ref-6861633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8137600','lexi-content-ref-Drew.2020','lexi-content-ref-6861633'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">High-dose extended-interval dosing (once-daily dosing): <b>IV:</b> 5 to 7 mg/kg once daily; use with caution in patients with CrCl &lt;40 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9142771','lexi-content-ref-12122533','lexi-content-ref-Drew.2020','lexi-content-ref-7793867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9142771','lexi-content-ref-12122533','lexi-content-ref-Drew.2020','lexi-content-ref-7793867'])">Ref</a></span>). Adjust tobramycin dose and interval to achieve an extrapolated peak concentration of ~15 to 20 mg/L and trough concentration &lt;0.5 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12122533','lexi-content-ref-Leggett.1','lexi-content-ref-7793867','lexi-content-ref-22085385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12122533','lexi-content-ref-Leggett.1','lexi-content-ref-7793867','lexi-content-ref-22085385'])">Ref</a></span>). <b>Note:</b> Published nomograms for dosage adjustment may not apply to patients with altered pharmacokinetics (eg, patients with ascites, burns covering &gt;20% total BSA, end-stage renal disease requiring dialysis, pregnancy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9142771','lexi-content-ref-7793867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9142771','lexi-content-ref-7793867'])">Ref</a></span>); some experts prefer traditional intermittent dosing in such populations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drew.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drew.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Indication-specific dosing:</b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection:</b>
<i>Adjunctive empiric therapy for patients with concern for resistant gram-negative bacteria (eg, immunosuppression, prevalent local resistance, recent antibiotic exposure)</i>: <b>IV:</b> 5 to 7 mg/kg once daily in combination with a second gram-negative active agent; once culture and susceptibility results are available, can generally discontinue and use a single agent with documented activity. Tobramycin should not be used as monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9142771','lexi-content-ref-Kanj.2020','lexi-content-ref-Moehring.2020','lexi-content-ref-7793867','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9142771','lexi-content-ref-Kanj.2020','lexi-content-ref-Moehring.2020','lexi-content-ref-7793867','lexi-content-ref-34599691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0161ba30-daf5-44e8-a055-5635faa343ea">Cerebrospinal fluid shunt infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cerebrospinal fluid shunt infection (adjunct to systemic therapy): Note:</b> Reserve for infections due to multidrug-resistant organisms, infections refractory to appropriate parenteral therapy, or when infected shunts cannot be removed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.1','lexi-content-ref-Friedman.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.1','lexi-content-ref-Friedman.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intraventricular</b> (use a preservative-free preparation): 5 to 20 mg/day; some experts recommend adjusting dosage and administration interval based on cerebrospinal fluid (CSF) tobramycin concentrations (goal: 10 to 20 times minimum inhibitory concentration of causative organism), ventricle size, and daily output from ventricular drain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>). When intraventricular tobramycin is administered via a ventricular drain, clamp drain for 15 to 60 minutes after administration (allows solution to equilibrate in CSF). Duration is individualized according to clinical and microbiological response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777','lexi-content-ref-27043949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777','lexi-content-ref-27043949'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d1d4c54-ef98-486f-9c71-c0e9856532b2">Cystic fibrosis, acute pulmonary exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, acute pulmonary exacerbation: </b>For empiric or targeted therapy of <i>P. aeruginosa </i>or other gram-negative bacilli:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 10 mg/kg once daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19729669','lexi-content-ref-20030477','lexi-content-ref-Simon.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19729669','lexi-content-ref-20030477','lexi-content-ref-Simon.2020'])">Ref</a></span>). Duration is usually 10 to 14 days depending on clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19729669','lexi-content-ref-34469706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19729669','lexi-content-ref-34469706'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial:</b>
<i>P. aeruginosa</i>: <b>IV:</b> 5 mg/kg/day in divided doses every 8 hours as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2f0164e-28ab-4d30-b893-da899a8afeac">Peritonitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis, treatment (peritoneal dialysis patients) (off-label use):</b> As a component of empiric therapy or for pathogen-directed therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Intraperitoneal administration is preferred to IV administration. Once culture results are available, switch to another active antibiotic class, if possible, to decrease the risk of toxicity; otherwise, duration of therapy is ≥3 weeks for patients with adequate clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Burkart.2020','lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Burkart.2020','lexi-content-ref-27282851'])">Ref</a></span>). Consider a 25% dose increase in patients with significant residual renal function (urine output &gt;100 mL/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20628102','lexi-content-ref-27282851','lexi-content-ref-29987068','lexi-content-ref-29987069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20628102','lexi-content-ref-27282851','lexi-content-ref-29987068','lexi-content-ref-29987069'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent (strongly preferred)</i>: <b>Intraperitoneal:</b> 0.6 mg/kg added to one exchange of dialysis solution once daily (allow to dwell ≥6 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous (with every exchange)</i>: <b>Intraperitoneal:</b> Loading dose: 3 mg/kg with first exchange of dialysate; maintenance dose: 0.3 mg/kg with each subsequent exchange of dialysate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="82c2b141-c61f-4f6a-9e90-3647d9c992d9">Plague, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague (<i>Yersinia pestis</i>), treatment (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM:</b> 5 to 7 mg/kg once daily for 7 to 14 days and for at least a few days after clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Stout.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Stout.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58f09831-e1d9-4d13-a555-4196b8a7ce81">Pneumonia, hospital-acquired or ventilator-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired or ventilator-associated (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Some experts reserve for patients with risk for multidrug-resistant pathogens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Klompas.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Klompas.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 5 to 7 mg/kg once daily in combination with a second gram-negative agent; once culture and susceptibility results are available, can generally discontinue tobramycin and use a single agent with documented activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577','lexi-content-ref-Klompas.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577','lexi-content-ref-Klompas.1'])">Ref</a></span>). <b>Note: </b> Avoid use of tobramycin monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="caf20c21-2d94-45c4-9b3f-1f0c2127b10d">Sepsis or septic shock, adjunctive empiric gram-negative coverage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sepsis or septic shock, adjunctive empiric gram-negative coverage (eg, in the setting of intra-abdominal infection, pneumonia, gram-negative bacteremia, or severe burn):</b>
<b>Note:</b> Some experts reserve for patients with immunocompromising conditions or risk for resistant gram-negative pathogens, in particular <i>P. aeruginosa </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanj.2020','lexi-content-ref-Moehring.2020','lexi-content-ref-Schmidt.2020','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanj.2020','lexi-content-ref-Moehring.2020','lexi-content-ref-Schmidt.2020','lexi-content-ref-34599691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 5 to 7 mg/kg once daily in combination with a second gram-negative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schmidt.2020','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schmidt.2020','lexi-content-ref-34599691'])">Ref</a></span>); once culture and susceptibility tests are available, can generally discontinue and use a single agent with documented activity. Tobramycin should not be used as monotherapy for severe infections outside of the urinary tract (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanj.2020','lexi-content-ref-7793867','lexi-content-ref-Schmidt.2020','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanj.2020','lexi-content-ref-7793867','lexi-content-ref-Schmidt.2020','lexi-content-ref-34599691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms) (alternative agent):</b>
<b>Note:</b> Some experts reserve for use when other long-acting parenteral antimicrobials (eg, ceftriaxone) or fluoroquinolones cannot be used due to allergy, intolerance, unmodifiable drug interactions, or resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Inpatients:</i>
<b>IV, IM:</b> 5 mg/kg once daily. Switch to an appropriate oral regimen once symptoms improve, if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.1','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.1','lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Outpatients:</i>
<b>IV, IM:</b> 5 mg/kg once, followed by 5 to 14 days of appropriate oral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.1','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.1','lexi-content-ref-21292654'])">Ref</a></span>). <b>Note:</b> For patients who are systemically ill or at risk for more severe illness, some experts continue daily parenteral therapy pending culture and susceptibility results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991938"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM, IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Conventional dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;60 mL/minute: Administer every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 40 to 60 mL/minute: Administer every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 20 to 39 mL/minute: Administer every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;20 mL/minute: Loading dose, then monitor levels.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">High-dose extended-interval dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9142771','lexi-content-ref-7793867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9142771','lexi-content-ref-7793867'])">Ref</a></span>): Interval may be extended (eg, every 36 to 48 hours) in patients with renal impairment and/or adjusted based on therapeutic drug monitoring.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥60 mL/minute: Administer every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 40 to 59 mL/minute: Administer every 36 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 20 to 39 mL/minute: Administer every 48 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;20 mL/minute: Monitor serum levels and redose when tobramycin level is &lt;1 mg/L or use conventional dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>): Dialyzable (25% to 70%; variable; dependent on filter, duration, and type of HD): <b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose of 2 to 3 mg/kg, followed by:</p>
<p style="text-indent:-2em;margin-left:8em;">Mild UTI: 1 mg/kg/dose every 48 to 72 hours; consider redosing for pre-HD or post-HD serum concentrations &lt;1 mg/L.</p>
<p style="text-indent:-2em;margin-left:8em;">Moderate to severe UTI: 1 to 1.5 mg/kg/dose every 48 to 72 hours; consider redosing for pre-HD serum concentrations &lt;1.5 to 2 mg/L or post-HD concentrations &lt;1 mg/L.</p>
<p style="text-indent:-2em;margin-left:8em;">Systemic gram-negative infection: 1.5 to 2 mg/kg/dose every 48 to 72 hours; consider redosing for pre-HD serum concentrations &lt;3 to 5 mg/L or post-HD serum concentrations &lt;2 mg/L.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>
<p style="text-indent:-2em;margin-left:4em;">CRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464','lexi-content-ref-16163635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464','lexi-content-ref-16163635'])">Ref</a></span>): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as target drug concentrations (if appropriate). <b>Note:</b> The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment; therapeutic drug monitoring is recommended:</p>
<p style="text-indent:-2em;margin-left:6em;">CVVH/CVVHD/CVVHDF: <b>IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Mild UTI: Loading dose of 2 to 3 mg/kg, followed by 1 mg/kg/dose every 24 to 36 hours (redose when serum concentration &lt;1 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>)).</p>
<p style="text-indent:-2em;margin-left:8em;">Moderate-severe UTI: Loading dose of 2 to 3 mg/kg, followed by 1 to 1.5 mg/kg/dose every 24 to 36 hours (redose when serum concentration &lt;1.5 to 2 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>)).</p>
<p style="text-indent:-2em;margin-left:8em;">Systemic gram-negative infection: Loading dose of 2 to 3 mg/kg, followed by 1.5 to 2.5 mg/kg/dose every 24 to 48 hours (generally accepted to redose when serum concentration &lt;2 mg/L; one reference suggests redosing when &lt;3 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>)).</p></div>
<div class="block doha drugH1Div" id="F50989197"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary; does not undergo hepatic metabolism.</p></div>
<div class="block adr drugH1Div" id="F45031146"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Confusion, disorientation, dizziness, headache, lethargy, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exfoliative dermatitis, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum calcium, decreased serum magnesium, decreased serum potassium, decreased serum sodium, increased lactate dehydrogenase, increased nonprotein nitrogen</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Casts in urine, oliguria, proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, eosinophilia, granulocytopenia, leukocytosis, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum ALT, increased serum AST, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory ototoxicity, hearing loss, tinnitus, vestibular ototoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, <i>Clostridioides difficile</i>-associated diarrhea, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>
<div class="block coi drugH1Div" id="F45031143"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to tobramycin, other aminoglycosides, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F45031144"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe allergic reactions (some fatal), including anaphylaxis, and dermatologic reactions (eg, exfoliative dermatitis, toxic epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome) have been reported; discontinue therapy and initiate appropriate treatment if allergic reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity:<b> [US Boxed Warning]: </b>
<b>May cause acute kidney injury, including acute renal failure. Risk factors include tobramycin accumulation (increasing serum trough levels), high peak concentrations (&gt;12 mcg/mL), total cumulative dose, advanced age, volume depletion, and concurrent or sequential use of other nephrotoxic drugs. Avoid concurrent or sequential use of other potentially nephrotoxic drugs. Monitor serum tobramycin levels and renal function in all patients during drug treatment. Reduce the dose or discontinue the drug if renal impairment occurs. </b>Kidney injury is usually reversible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular blockade:<b> [US Boxed Warning]: </b>
<b>Aminoglycosides have been associated with neuromuscular blockade. Monitor for adverse reactions associated with neuromuscular blockade during therapy, particularly in high-risk patients, such as patients with underlying neuromuscular disorders (including myasthenia gravis) or in patients concomitantly receiving neuromuscular-blocking agents. </b>Neuromuscular blockade may lead to respiratory failure and prolonged respiratory paralysis; additional signs of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions. Neuromuscular blockade is reversible but may require treatment (eg, administration of calcium salts).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ototoxicity: <b>[US Boxed Warning]: May </b>
<b>cause irreversible auditory and vestibular toxicity that may continue to develop after discontinuation. Risk factors include high serum concentrations, prolonged therapy, renal impairment, concurrent and sequential use of other nephrotoxic or ototoxic drugs (eg, aminoglycosides), and extremes of age. Avoid concurrent or sequential use with other potentially ototoxic drugs. Monitor for signs and symptoms of auditory and vestibular toxicity. Reduce the dose or discontinue therapy if renal impairment occurs. Discontinue use if ototoxicity occurs. </b>Auditory changes are usually bilateral and may be partial or total. Ototoxicity symptoms may include dizziness, vertigo, tinnitus, roaring in the ears and hearing loss; consider serial audiograms in high-risk patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hearing impairment: Use with caution in patients with pre-existing vertigo, tinnitus, or hearing loss.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia: Use with caution in patients with hypocalcemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis and Parkinson disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with preexisting renal insufficiency; dosage modification required during systemic therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with genomic variants in MT-RNR1: Carriers of certain variants in the MT-RNR1 gene (eg, m.1555A&gt;G) may be at increased risk for aminoglycoside-induced ototoxicity, including potentially significant hearing loss that may be irreversible, even when serum levels are within the normal range.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfite: Solution for injection may contain sodium metabisulfate; use caution in patients with sulfite allergy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for intraocular and/or subconjunctival administration; macular necrosis has been reported following administration of aminoglycosides by these routes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Long-term use: Systemic therapy is not intended for long-term therapy due to toxic hazards associated with extended administration.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878806"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use with caution in premature infants and neonates; immature renal function may increase risk of accumulation and related toxicity. Use with caution in pediatric patients on extracorporeal membrane oxygenation (ECMO); pharmacokinetics of aminoglycosides may be altered; dosage adjustment and close monitoring necessary. </p></div>
<div class="block foc drugH1Div" id="F45031190"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (2 mL); 80 mg/2 mL (2 mL); 1.2 g/30 mL (30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 80 mg/2 mL (2 mL); 2 g/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.2 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F45031130"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F45031194"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Tobramycin Sulfate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.2 g/30 mL (per mL): $0.86 - $0.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 gm/50 mL (per mL): $1.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $3.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/2 mL (per mL): $0.93 - $2.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Tobramycin Sulfate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.2 g (per each): $86.40 - $218.75</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872036"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg/mL (2 mL, 30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.2 g (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52614623"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM: May be administered undiluted.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer by intermittent infusion over 20 to 60 minutes; shorter infusion times (≤5 minutes) have been reported in pediatric patients, including preterm and term neonates, receiving ≤4 mg/kg/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31492162','lexi-content-ref-25388408','lexi-content-ref-11724077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31492162','lexi-content-ref-25388408','lexi-content-ref-11724077'])">Ref</a></span>). Avoid infusing concomitantly with penicillins or cephalosporins if feasible; consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal/Intraventricular: Use preservative-free preparations only; must be diluted prior to administration. No specific administration information available; it has been suggested that instillation of small volumes (&lt;3 mL) over 1 to 2 minutes is safe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19558257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19558257'])">Ref</a></span>). When administered through a ventricular drain, clamp drain for 15 to 60 minutes to allow tobramycin solution to equilibrate in the cerebrospinal fluid (CSF) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F45031174"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> May be administered IM by withdrawing the appropriate dose directly from a vial or by using a prefilled syringe. The pharmacy bulk package and tobramycin in sodium chloride 0.9% is not intended for IM administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer by intermittent infusion over 20 to 60 minutes; higher doses are generally administered over 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12356801','lexi-content-ref-9145878']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12356801','lexi-content-ref-9145878'])">Ref</a></span>). Flush line with saline before and after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraventricular (off-label route):</b> Use preservative-free preparations only. When administered through a ventricular drain, clamp drain for 15 to 60 minutes before opening the drain to allow tobramycin solution to equilibrate in the CSF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F45031148"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 20ºC to 25ºC (68ºF to 77ºF). Reconstituted solutions remain stable for 24 hours at room temperature and 96 hours when refrigerated.</p></div>
<div class="block usep drugH1Div" id="F53571310"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of bloodstream infections caused by susceptible<i> Escherichia coli</i>,<i> Klebsiella </i>spp., and <i>Pseudomonas aeruginosa</i>; treatment of lower respiratory tract infections caused by susceptible <i>E. coli</i>,<i> Enterobacter spp.</i>,<i> Klebsiella</i> spp., <i>P. aeruginosa</i>,<i> Serratia </i>spp., and <i>Staphylococcus aureus</i>; treatment of meningitis caused by susceptible bacteria; treatment of intra-abdominal infections, including peritonitis, caused by susceptible <i>E. coli</i>, <i>Enterobacter </i>spp., and <i>Klebsiella</i> spp.; treatment of skin and skin structure infections caused by susceptible <i>E. coli</i>,<i> Enterobacter </i>spp., <i>Klebsiella </i>spp., <i>P. aeruginosa</i>, <i>Proteus</i> spp., and <i>S. aureus</i>; treatment of bone infections caused by susceptible <i>E. coli</i>,<i> Enterobacter </i>spp., <i>Klebsiella </i>spp., <i>P. aeruginosa</i>, <i>Proteus</i> spp., and <i>S. aureus; </i>treatment of complicated urinary tract infections caused by susceptible <i>Citrobacter </i>spp., <i>E. coli, Enterobacter </i>spp., <i>Klebsiella </i>spp., <i>P. aeruginosa</i>, <i>Proteus</i> spp., <i>Providencia</i> spp., and <i>S. aureus</i> (All indications: FDA approved in all ages); has also been used for treatment of endocarditis, treatment of pulmonary infection in cystic fibrosis, and intra-peritoneally for treatment of peritonitis.</p></div>
<div class="block mst drugH1Div" id="F45031120"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tobramycin may be confused with Trobicin, vancomycin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nebcin [Multiple international markets] may be confused with Naprosyn brand name for naproxen [US, Canada, and multiple international markets]; Nubain brand name for nalbuphine [Multiple international markets]</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F45031205"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F45031202"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the nephrotoxic effect of other Aminoglycosides. Aminoglycosides may enhance the neurotoxic effect of other Aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides. Amphotericin B may enhance the neurotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacitracin (Systemic): May enhance the nephrotoxic effect of Aminoglycosides. Bacitracin (Systemic) may enhance the neurotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. Aminoglycosides may enhance the nephrotoxic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: Aminoglycosides may enhance the neuromuscular-blocking effect of Botulinum Toxin-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CARBOplatin: May enhance the nephrotoxic effect of Aminoglycosides. Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalosporins: May enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CISplatin: May enhance the nephrotoxic effect of Aminoglycosides. CISplatin may enhance the neurotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.  Management: Avoid coadministration of colistimethate and aminoglycosides whenever possible due to the risk of nephrotoxicity and neuromuscular blockade. If coadministration cannot be avoided, monitor renal and neuromuscular function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclizine: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netilmicin (Ophthalmic): Aminoglycosides may enhance the nephrotoxic effect of Netilmicin (Ophthalmic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Aminoglycosides may enhance the therapeutic effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymyxin B: May enhance the nephrotoxic effect of Aminoglycosides. Polymyxin B may enhance the neurotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Aminoglycosides may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides. Vancomycin may enhance the neurotoxic effect of Aminoglycosides. Management: Consider avoiding coadministration of aminoglycosides and vancomycin unless clinically indicated. If coadministered, monitor closely for signs of nephrotoxicity and neurotoxicity.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F45031173"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May require supplementation of calcium, magnesium, potassium.</p></div>
<div class="block pri drugH1Div" id="F45031139"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Tobramycin crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Tobramycin and other aminoglycosides can cause fetal harm when administered to a pregnant patient. If tobramycin is used during pregnancy or if the patient becomes pregnant while taking tobramycin, apprise the patient of the potential hazard to the fetus.</p>
<p style="text-indent:0em;margin-top:2em;">There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy. Although serious side effects to the fetus/infant have not been reported following maternal use of all aminoglycosides, a potential for harm exists.</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of tobramycin may be altered (Bourget 1991).</p>
<p style="text-indent:0em;margin-top:2em;">Tobramycin injection may be used for the management of cystic fibrosis in pregnant patients with <i>P. aeruginosa</i> (inhalation is preferred unless risk of infection is great) (Edenborough 2008) and as an alternative antibiotic for prophylactic use prior to cesarean delivery (Bratzler 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Tobramycin is used in the management of plague (<i>Yersinia pestis</i>). Untreated infections in pregnant patients may result in hemorrhage (including postpartum hemorrhage), maternal and fetal death, preterm birth, and stillbirth. Limited data suggest maternal-fetal transmission of <i>Y. pestis</i> can occur if not treated. Pregnant patients should be treated for <i>Y. pestis</i>; parenteral antibiotics are preferred for initial treatment when otherwise appropriate. Tobramycin is an alternative aminoglycoside recommended for use (in combination with a fluroquinolone) for treating pregnant patients with bubonic, pharyngeal, pneumonic, or septicemic plague (CDC [Nelson 2021]).</p></div>
<div class="block mopp drugH1Div" id="F53571309"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Urinalysis, urine output, BUN, SCr, hearing test (especially for those at risk of ototoxicity or who will be receiving prolonged therapy [&gt;2 weeks]).</p>
<p style="text-indent:-2em;margin-left:2em;">Serum tobramycin concentrations: <b>Note:</b> Avoid fingerstick blood samples for monitoring serum tobramycin concentrations in patients concurrently receiving inhaled tobramycin; results may be falsely elevated (Redmann 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conventional dosing:</i> Initial serum concentrations typically obtained after the third dose; may consider obtaining serum concentrations sooner in neonates or patients with rapidly changing renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended-interval dosing:</i> Initial serum concentrations may be obtained following the first or second dose (Begg 1999; Knoderer 2003).</p>
<p style="text-indent:-2em;margin-left:2em;">Patients receiving outpatient therapy: Serum tobramycin concentrations (at least weekly); CBC with differential (weekly); basic metabolic panel including potassium, creatinine, and BUN (twice weekly) (Norris 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Not all pediatric patients who receive aminoglycosides require monitoring of serum aminoglycoside concentrations. Indications for use of aminoglycoside serum concentration monitoring include:</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment course &gt;5 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with decreased or changing renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with a poor therapeutic response.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and Infants &lt;3 months of age.</p>
<p style="text-indent:-2em;margin-left:4em;">Atypical body constituency (obesity, expanded extracellular fluid volume).</p>
<p style="text-indent:-2em;margin-left:4em;">Clinical need for higher doses or shorter intervals (cystic fibrosis, burns, endocarditis, meningitis, relatively resistant organism).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients on hemodialysis or chronic ambulatory peritoneal dialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">Signs of nephrotoxicity or ototoxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">Concomitant use of other nephrotoxic agents.</p>
<p style="text-indent:-2em;margin-left:2em;">Some beta-lactam agents (penicillins and cephalosporins) may accelerate the degradation of aminoglycosides in vitro; this may be clinically significant in patients with significant renal impairment. Close monitoring of aminoglycoside concentrations and clinical response is warranted.</p></div>
<div class="block rerp drugH1Div" id="F53570603"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note</b>: Sampling times and target concentrations provided reflect general practices; patient-specific factors, including type and site of infection, goals of therapy, severity of illness, clinical status, fluid status, and kidney function should be considered when determining patient-specific therapeutic monitoring plans and targets. Outcomes are predicted by serum concentrations and the minimum inhibitory concentration (MIC) of the infecting organism. Efficacy has been associated with peak:MIC ratios of ≥8 to 10 and AUC<sub>24</sub>:MIC ratios of 30 to 100 depending on severity of infection (Bland 2018; Craig 2011; Knoderer 2003). Nephrotoxicity is associated with elevated trough concentrations (Bertino 1993; Rybak 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Neonates:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Timing of serum samples (El-Chaar 2016; Touw 2009; van Donge 2018; van Maarseveen 2016; manufacturer's labeling):</p>
<p style="text-indent:-2em;margin-left:6em;">Peak: 30 minutes after end of 30-minute infusion, or 1 hour following start of infusion or IM injection.</p>
<p style="text-indent:-2em;margin-left:6em;">Trough: End of dosing interval, just prior to the next dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Target concentrations: <b>Note:</b> Studies evaluating extended-interval dosing in neonates typically target concentrations more often associated with conventional dosing (Miller 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak: ≥8 to 12 mg/L; 10 x MIC (El-Chaar 2016; Touw 2009; van Maarseveen 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">Trough: &lt;0.5 to 1 mg/L (Touw 2009; van Maarseveen 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Infants, Children, and Adolescents:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Conventional dosing</b>:</p>
<p style="text-indent:-2em;margin-left:6em;">Timing of serum samples:</p>
<p style="text-indent:-2em;margin-left:8em;">Peak: 30 minutes after 30-minute infusion, or 1 hour following start of infusion or IM injection.</p>
<p style="text-indent:-2em;margin-left:8em;">Trough: End of dosing interval, immediately before next dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Target concentrations:</p>
<p style="text-indent:-2em;margin-left:8em;">Peak:</p>
<p style="text-indent:-2em;margin-left:10em;">General: 6 to 12 mg/L or 10 x MIC (<i>Red Book </i>[AAP 2021]). <b>Note</b>: Peak concentrations on the lower end of the range would only achieve efficacy target (10 x MIC) for MICs ≤0.5 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Urinary tract infections: 4 to 6 mg/L (Matzke 1983).</p>
<p style="text-indent:-2em;margin-left:10em;">Synergy against gram-positive organisms (based on gentamicin): 3 to 4 mg/L (AHA [Baltimore 2015]).</p>
<p style="text-indent:-2em;margin-left:8em;">Trough:</p>
<p style="text-indent:-2em;margin-left:10em;">General: &lt;1 to 2 mg/L (Hammett-Stabler 1998; <i>Red Book </i>[AAP 2021]); others suggest a target of &lt;0.5 to 1 mg/L (Bland 2018; Touw 2009).</p>
<p style="text-indent:-2em;margin-left:10em;">Synergy against gram-positive organisms (based on gentamicin): &lt;1 mg/L (AHA [Baltimore 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended-interval dosing: Note:</b> Monitoring protocols are not standardized; various approaches exist. In addition to the strategies discussed, AUC monitoring has also been described (Begg 1999; Bland 2018; Roy 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">Timing of serum samples:</p>
<p style="text-indent:-2em;margin-left:8em;">Peak: 30 minutes after the end of a 30-minute infusion (Jenh 2011; Knoderer 2003). Some suggest waiting ≥60 minutes after the end of the infusion to allow time for distribution of higher doses, and using patient-specific pharmacokinetic parameters to back-extrapolate true peak concentration (Prescott 2010; Safi 2016). It is not always necessary to monitor peak concentration depending on clinical situation (Begg 1999; Jenh 2011).</p>
<p style="text-indent:-2em;margin-left:8em;">Trough: Obtain at the end of a dosing interval, just prior to the next dose (Begg 1999; Knoderer 2003). May also obtain 4 hours prior to the next dose to ensure that drug has cleared (McDade 2010).</p>
<p style="text-indent:-2em;margin-left:8em;">Patient-specific calculations: Two concentrations at least one half-life apart can be obtained (eg, a peak and a mid-interval concentration 8 to 12 hours after the dose, or 2 postdistribution concentrations while drug is still detectable) to calculate patient-specific pharmacokinetic parameters and extrapolate peak, trough, AUC, and/or drug-free interval (Jenh 2011; Knoderer 2003). For patients with cystic fibrosis, the 2 random samples postinfusion is the most common strategy used to monitor aminoglycosides (eg, obtain a serum concentration 2 hours and 8 to 10 hours after the start of the infusion, calculate elimination rate, and extrapolate peak and trough) (Zobell 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">Target concentrations:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients without cystic fibrosis:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Peak: 8 to 10 x MIC of the pathogen (~15 to 35 mg/L) (Jenh 2011; Knoderer 2003; Roy 2016).</p>
<p style="text-indent:-2em;margin-left:10em;">Trough: &lt;0.5 to 1 mg/L; ideally undetectable; a drug-free period is desired (Jenh 2011; Knoderer 2003; McDade 2010).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients with cystic fibrosis:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Peak: 20 to 30 mg/L (Safi 2016; Smyth 2005); target range variable; higher target concentrations up to 40 mg/L have been reported (Flume 2009; Zobell 2016). May be necessary to modify target based on MIC to achieve targets associated with efficacy (Burkhardt 2006).</p>
<p style="text-indent:-2em;margin-left:10em;">Trough: &lt;0.5 to 1 mg/L; undetectable (Flume 2009; Safi 2016; Wassil 2008; Zobell 2016). A drug-free period is desired; some centers adjust dose to provide a drug-free interval of ≤8 to 12 hours (Zobell 2016).</p>
<p style="text-indent:-2em;margin-left:10em;">AUC: 75 to 125 mg•hr/L; most centers target 80 to 120 mg•hr/L (Zobell 2016).</p></div>
<div class="block pha drugH1Div" id="F45031152"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferes with bacterial protein synthesis by binding to 30S ribosomal subunit, resulting in a defective bacterial cell membrane</p></div>
<div class="block phk drugH1Div" id="F45031155"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Poorly absorbed.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Rapid and complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributes to extracellular fluid, including serum, abscesses, ascitic, pericardial, pleural, synovial, lymphatic, and peritoneal fluids; poor penetration into CSF, eye, bone, prostate.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: Varies with age; increased in patients with edema, ascites, fluid overload; decreased in patients with dehydration:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: 0.45 ± 0.1 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: 0.4 ± 0.1 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Children: 0.35 ± 0.15 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: 0.3 ± 0.1 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.2 to 0.3 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">CSF:blood level ratio: Normal meninges: &lt;10%; Inflamed meninges: ≤25% (MacDougall 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Lung: Epithelial lining fluid C<sub>max</sub> (peak):serum C<sub>max</sub> (peak) ratio: ~12% to 30%, varies with time (Boselli 2007; Carcas 1999; Heffernan 2019; Rodvold 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;30%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: ≤1,200 g: 11 hours; &gt;1,200 g: 2 to 9 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: 4 ± 1 hour.</p>
<p style="text-indent:-2em;margin-left:4em;">Children: 2 ± 1 hour.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: 1.5 ± 1 hour.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: IV: 2 to 3 hours; directly dependent upon glomerular filtration rate.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults with impaired renal function: 5 to 70 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: 30 to 60 minutes; IV: ~30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Distribution is prolonged after larger doses (≥60 minutes after 60-minute infusion of 10 mg/kg [Aminimanizani 2002]; ≥90 minutes after 60-minute infusion of a high-dose aminoglycoside [gentamicin 7 mg/kg] [Demczar 1997]).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Normal renal function: Urine (~90% to 95%) within 24 hours.</p></div>
<div class="block phksp drugH1Div" id="F51204289"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is decreased in renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Gram-negative bacilli: Concentration-dependent, associated with C<sub>max</sub> (peak)/minimum inhibitory concentration (MIC), goal: ≥8 to 10 (Craig 2011; Kashuba 1999; Moore 1987; Zelenitsky 2003) or AUC<sub>24</sub>/MIC, goal: 30 to 50 (mild/moderate infection) or 80 to 100 (severe infection) (Bland 2018; Craig 2011; Drusano 2007; Smith 2001).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>P. aeruginosa</i> in patients with cystic fibrosis: C<sub>max</sub> (peak)/MIC ≥10, AUC/MIC ≥50 (Burkhardt 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Expected drug exposure in adults with normal renal function:</p>
<p style="text-indent:-2em;margin-left:6em;">C<sub>max</sub> (peak), postdistributional: 7 mg/kg: ~20 to 22 mg/mL (Craig 2011; Finnell 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">AUC<sub>24</sub>:</p>
<p style="text-indent:-2em;margin-left:8em;">Cystic fibrosis:</p>
<p style="text-indent:-2em;margin-left:10em;">10 mg/kg: ~108 mg•hour/L (Aminimanizani 2002).</p>
<p style="text-indent:-2em;margin-left:10em;">7 mg/kg: 70 to 110 mg•hour/L (Barclay 1995; Craig 2011; Finnell 1998).</p>
<p style="text-indent:-2em;margin-left:8em;">Critically ill: 5 mg/kg: ~86 mg•hour/L (Conil 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with toxicity:</i> Nephrotoxicity is associated with more frequent administration and elevated C<sub>min</sub> (trough) concentrations leading to renal accumulation (Bertino 1993; Rybak 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Bacterial killing continues after tobramycin concentration drops below the MIC of targeted pathogen; generally 0.5 to 7.5 hours, though the actual time of postantibiotic effect varies based on multiple factors including organism, tobramycin C<sub>max</sub> (peak), and concomitant antimicrobial therapy (Craig 2011; Gudmundsson 1993; Lacy 1998).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45649945"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Nebcin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Tobral | Tobramicina gen med</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tobramycin b.braun | Tobrasix</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Nebcin | Tobra Day | Tobramycin | Tobramycin mylan | Tobramycin wockhardt</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Brulamycin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Obracin | Tobramycine B. Braun | Tobramycine mayne pharma (ben)</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Tobramycin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Tobramina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Obracin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Nuo neng | Tai xing | Tobramycin | Tobramycin sulfate | Tuo xin | Yu er ning</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Tobra</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Brulamycin | Nebcin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Gernebcin | Tobra | Tobra cell | Tobramycin b.braun | Tobramycin MP | Tobrazid</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Nebcina | Tobra gobens</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Brulamycin | Gernebcin | Nebcin | Obracin | Tobramicin | Tobramycin MP | Tobrazid | Tocin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Nebcin | Tobra alex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tobra gobens | Tobramicina normon</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Nebcina | Tobramycin B Braun | Tomycin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Nebcine | Tobramycine b braun | Tobramycine merck</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Nebcin | Tobramycin | Tobramycin cox</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Medphatobra | Nebcin | Tobramycin | Tobramycin Actavis | Tobramycin MP</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Nebcin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Brulamycin | Nebcin | Tobramycine cf</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Dartobcin | Tobramycin | Tobryne</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Nebcin | Tobramycin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Nebcin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Nebracin | Tobacin | Tobex | Tobraneg | Tocin | Toracin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bramicil | Nebicina | Tobramicina | Tobramicina B. Braun</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Nebcin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Tobracin eli lilly | Tobracin jdolph</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Binex tobramycin | Korus tobramycin | Mytob | Nebcin | Pharmedix tobramycin | Samjin tobramycin | Tenebra | Toberan | Tobicyran | Tobra | Tobramycin | Tobramycin huons | Tobramycin pre-mix | Tobramycin sulfate huons | Tobroxine | Tobucin | Tronamycin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Nebcin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Brulamycin | Nebcin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Obracin | Tobramycin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Brulamycin | Nebcin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Nebcine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Tobra</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Obracin | Tobramycine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Nebcin | Nebcina | Tobramycin B. Braun | Tobramycin x gen</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Nebcin | Tobra Day | Tobramycin | Tobramycin mylan | Tobramycin viatris</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Nebcin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Abbocin | Brulamycin | Magracin | Nebcin | Obramycin | Tobcin | Tobracil | Tobracin | Tobramed | Tobrin | Tocin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Brulamycin | Nebcine | Obracin | Tobramycin MP</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nebcin | Tobramycin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Distobram | Tobra gobens | Tobramicina B. Braun | Tobramicina labesfal</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Tobramicina quimfa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Tobramicina sun</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Brulamycin | Nebcin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Nebcin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Nebcina</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Tobramycin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bramitob | Gernebicin | Nebcin | Tobramicina normon</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Brulamycin | Tobramycin b.braun</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Nebcin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Nebcine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Nebcin | Tobel</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Biomicin | Nebcin | Tobcin | Tobra | Tobucin | Topramycin | Topsin | Zerodiar</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Braxon | Brulamycin | Tobramycin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Tobra | Tobramicina</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Intolacin | Union tobracin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Micro tobramycin | Nebcin | Q-med tobramycin | Tobramycin-fresenius</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21873693">
<a name="21873693"></a>American Academy of Pediatrics, Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics</i>. 2011;128(3):595-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/21873693/pubmed" id="21873693" target="_blank">21873693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12356801">
<a name="12356801"></a>Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. <i>J Antimicrob Chemother.</i> 2002;50(4):553-559. doi:10.1093/jac/dkf168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12356801/pubmed" id="12356801" target="_blank">12356801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36009990">
<a name="36009990"></a>Autore G, Bernardi L, La Scola C, et al. Management of pediatric urinary tract infections: a Delphi study. <i>Antibiotics (Basel)</i>. 2022;11(8):1122. doi:10.3390/antibiotics11081122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/36009990/pubmed" id="36009990" target="_blank">36009990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.1">
<a name="Baddour.1"></a>Baddour L, Flynn PM, Fekete T. Infections of cerebrospinal fluid shunts and other devices. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 12, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9142771">
<a name="9142771"></a>Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. <i>Clin Infect Dis</i>. 1997;24(5):786-795. doi:10.1093/clinids/24.5.786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/9142771/pubmed" id="9142771" target="_blank">9142771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29292282">
<a name="29292282"></a>Balighian E, Burke M. Urinary tract infections in children. <i>Pediatr Rev</i>. 2018;39(1):3-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/29292282/pubmed" id="29292282" target="_blank">29292282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7487691">
<a name="7487691"></a>Barclay ML, Duffull SB, Begg EJ, Buttimore RC. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. <i>Aust N Z J Med.</i> 1995;25(3):230-235. doi:10.1111/j.1445-5994.1995.tb01529.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/7487691/pubmed" id="7487691" target="_blank">7487691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10885841">
<a name="10885841"></a>Bartel K, Habash T, Lugauer S, et al. Optimal Tobramycin Dosage in Patients With Cystic Fibrosis − Evidence for Predictability Based on Previous Drug Monitoring. <i>Infection.</i> 1999;27(4-5):268-271.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/10885841/pubmed" id="10885841" target="_blank">10885841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7325627">
<a name="7325627"></a>Bauer LA, Blouin RA. Influence of Age on Tobramycin. Pharmacokinetics in Patients With Normal Renal Function. <i>Antimicrob Agents Chemother.</i> 1981;20(5):587-589. doi:10.1128/aac.20.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/7325627/pubmed" id="7325627" target="_blank">7325627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10073735">
<a name="10073735"></a>Begg EJ, Barclay ML, Kirkpatrick CJ. The therapeutic monitoring of antimicrobial agents. <i>Br J Clin Pharmacol</i>. 1999;47(1):23-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/10073735/pubmed" id="10073735" target="_blank">10073735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31492162">
<a name="31492162"></a>Bergenwall M, Walker SAN, Elligsen M, et al. Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation - a retrospective study. <i>BMC Pediatr</i>. 2019;19(1):318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/31492162/pubmed" id="31492162" target="_blank">31492162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8418164">
<a name="8418164"></a>Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. <i>J Infect Dis.</i> 1993;167(1):173-179. doi:10.1093/infdis/167.1.173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/8418164/pubmed" id="8418164" target="_blank">8418164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8137600">
<a name="8137600"></a>Bertino JS Jr, Rodvold KA, Destache CJ. Cost considerations in therapeutic drug monitoring of aminoglycosides. <i>Clin Pharmacokinet</i>. 1994;26(1):71-81. doi:10.2165/00003088-199426010-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/8137600/pubmed" id="8137600" target="_blank">8137600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25455848">
<a name="25455848"></a>Blackburn LM, Tverdek FP, Hernandez M, Bruno JJ. First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients. <i>Int J Antimicrob Agents</i>. 2015;45(1):46-53. doi:10.1016/j.ijantimicag.2014.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/25455848/pubmed" id="25455848" target="_blank">25455848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30403305">
<a name="30403305"></a>Bland CM, Pai MP, Lodise TP. Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing. <i>Pharmacotherapy</i>. 2018;38(12):1229-1238. doi:10.1002/phar.2193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/30403305/pubmed" id="30403305" target="_blank">30403305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17530217">
<a name="17530217"></a>Boselli E, Breilh D, Djabarouti S, et al. Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. <i>Intensive Care Med</i>. 2007;33(9):1519-1523. doi:10.1007/s00134-007-0688-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/17530217/pubmed" id="17530217" target="_blank">17530217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1869596">
<a name="1869596"></a>Bourget P, Fernandez H, Delouis C, et al. Pharmacokinetics of Tobramycin in Pregnant Women. Safety and Efficacy of a Once-Daily Dose Regimen. <i>J Clin Pharm Ther.</i> 1991;16(3):167-176.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/1869596/pubmed" id="1869596" target="_blank">1869596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Microbial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12739981">
<a name="12739981"></a>Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. <i>Clin Pharmacokinet</i>. 2003;42(5):403-417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12739981/pubmed" id="12739981" target="_blank">12739981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12122533">
<a name="12122533"></a>Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. <i>Intensive Care Med</i>. 2002;28(7):936-942. doi:10.1007/s00134-002-1313-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12122533/pubmed" id="12122533" target="_blank">12122533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burkart.2020">
<a name="Burkart.2020"></a>Burkart JM. Microbiology and therapy of peritonitis in peritoneal dialysis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16885180">
<a name="16885180"></a>Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? <i>J Antimicrob Chemother</i>. 2006;58(4):822-829. doi:10.1093/jac/dkl328<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/16885180/pubmed" id="16885180" target="_blank">16885180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23896470">
<a name="23896470"></a>Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP. Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation. <i>Antimicrob Agents Chemother.</i> 2013;57(10):5175-5177. doi:10.1128/AAC.00539-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/23896470/pubmed" id="23896470" target="_blank">23896470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11303823">
<a name="11303823"></a>Carapetis JR, Jaquiery AL, Buttery JP, et al. Randomized, Controlled Trial Comparing Once Daily and Three Times Daily Gentamicin in Children With Urinary Tract Infections. <i>Pediatr Infect Dis J.</i> 2001;20(3):240-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/11303823/pubmed" id="11303823" target="_blank">11303823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10096256">
<a name="10096256"></a>Carcas AJ, García-Satué JL, Zapater P, Frías-Iniesta J. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. <i>Clin Pharmacol Ther.</i> 1999;65(3):245-250. doi:10.1016/S0009-9236(99)70103-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/10096256/pubmed" id="10096256" target="_blank">10096256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6798229">
<a name="6798229"></a>Chow MS, Quintiliani, Nightingale CH. <i>In Vivo</i> Inactivation of Tobramycin by Ticarcillin. A Case Report. <i>JAMA.</i> 1982;247(5):658-659.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/6798229/pubmed" id="6798229" target="_blank">6798229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12431134">
<a name="12431134"></a>Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12431134/pubmed" id="12431134" target="_blank">12431134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21143502">
<a name="21143502"></a>Conil JM, Georges B, Ruiz S, et al. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. <i>Br J Clin Pharmacol.</i> 2011;71(1):61-71. doi:10.1111/j.1365-2125.2010.03793.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/21143502/pubmed" id="21143502" target="_blank">21143502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19558257">
<a name="19558257"></a>Cook AM, Mieure KD, Owen RD, Pesaturo AB, Hatton J. Intracerebroventricular administration of drugs. <i>Pharmacotherapy</i>. 2009;29(7):832-845. doi: 10.1592/phco.29.7.832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19558257/pubmed" id="19558257" target="_blank">19558257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15231982">
<a name="15231982"></a>Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al. Extended-Interval Aminoglycoside Administration for Children: A Meta-Analysis. <i>Pediatrics.</i> 2004;114(1):e111-e118.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/15231982/pubmed" id="15231982" target="_blank">15231982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21144989">
<a name="21144989"></a>Craig WA. Optimizing aminoglycoside use. <i>Crit Care Clin</i>. 2011;27(1):107-121. doi:10.1016/j.ccc.2010.11.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/21144989/pubmed" id="21144989" target="_blank">21144989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9069064">
<a name="9069064"></a>Daly JS, Dodge RA, Glew RH, et al. Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages. <i>J Perinatol.</i> 1997;17(1):42-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/9069064/pubmed" id="9069064" target="_blank">9069064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12011820">
<a name="12011820"></a>de Hoog M, Mouton JW, Schoemaker RC, et al. Extended-Interval Dosing of Tobramycin in Neonates: Implications for Therapeutic Drug Monitoring. <i>Clin Pharmacol Ther</i>. 2002;71(5):349-358.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12011820/pubmed" id="12011820" target="_blank">12011820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9145878">
<a name="9145878"></a>Demczar DJ, Nafziger AN, Bertino JS Jr. Pharmacokinetics of Gentamicin at Traditional Versus High Doses: Implications for Once-Daily Aminoglycoside Dosing. <i>Antimicrob Agents Chemother.</i> 1997;41(5):1115-1119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/9145878/pubmed" id="9145878" target="_blank">9145878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12741432">
<a name="12741432"></a>DiCenzo R, Forrest A, Slish JC, et al. A Gentamicin Pharmacokinetic Population Model and Once-Daily Dosing Algorithm for Neonates. <i>Pharmacotherapy</i>. 2003;23(5):585-591.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12741432/pubmed" id="12741432" target="_blank">12741432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11549103">
<a name="11549103"></a>Dowell JA, Korth-Bradley J, Milisci M, et al. Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment. <i>J Clin Pharmacol.</i> 2001;41:979-986.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/11549103/pubmed" id="11549103" target="_blank">11549103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drew.2020">
<a name="Drew.2020"></a>Drew RH. Dosing and administration of parenteral aminoglycosides. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17712761">
<a name="17712761"></a>Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. <i>Clin Infect Dis</i>. 2007;45(6):753-760. doi:10.1086/520991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/17712761/pubmed" id="17712761" target="_blank">17712761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18024241">
<a name="18024241"></a>Edenborough FP, Borgo G, Knoop C, et al. Guidelines for the management of pregnancy in women with cystic fibrosis. <i>J Cyst Fibros</i>. 2008;7(suppl 1):S2-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/18024241/pubmed" id="18024241" target="_blank">18024241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26986995">
<a name="26986995"></a>El-Chaar GM, Supaswud-Franks T, Venugopalan L, Kohn N, Castro-Alcaraz S. Extended-interval gentamicin administration in neonates: a simplified approach. <i>J Perinatol</i>. 2016;36(8):660-665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/26986995/pubmed" id="26986995" target="_blank">26986995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599691">
<a name="34599691"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.<i> Intensive Care Med.</i> 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/34599691/pubmed" id="34599691" target="_blank">34599691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16801316">
<a name="16801316"></a>Festini F, Ciuti R, Taccetti G, et al. Breast-Feeding in a Woman With Cystic Fibrosis Undergoing Antibiotic Intravenous Treatment. <i>J Matern Fetal Neonatal Med</i>. 2006;19(6):375-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/16801316/pubmed" id="16801316" target="_blank">16801316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9562135">
<a name="9562135"></a>Finnell DL, Davis GA, Cropp CD, Ensom MH. Validation of the Hartford nomogram in trauma surgery patients. <i>Ann Pharmacother.</i> 1998;32(4):417-421. doi:10.1345/aph.17243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/9562135/pubmed" id="9562135" target="_blank">9562135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19729669">
<a name="19729669"></a>Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations. <i>Am J Respir Crit Care Med</i>. 2009;180(9):802-808.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19729669/pubmed" id="19729669" target="_blank">19729669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32364593">
<a name="32364593"></a>Fox MT, Amoah J, Hsu AJ, Herzke CA, Gerber JS, Tamma PD. Comparative effectiveness of antibiotic treatment duration in children with pyelonephritis. <i>JAMA Netw Open</i>. 2020;3(5):e203951. doi:10.1001/jamanetworkopen.2020.3951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/32364593/pubmed" id="32364593" target="_blank">32364593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Friedman.2020">
<a name="Friedman.2020"></a>Friedman ND, Sexton DJ. Gram-negative bacillary meningitis: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 12, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gilbert.1">
<a name="Gilbert.1"></a>Gilbert DN and Leggett JE. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, eds. <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.</i> 7th ed. Churchill Livingstone Elsevier; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2039189">
<a name="2039189"></a>Gilbert DN. Once-Daily Aminoglycoside Therapy. <i>Antimicrob Agents Chemother</i>. 1991;35(3):399-405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/2039189/pubmed" id="2039189" target="_blank">2039189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30397061">
<a name="30397061"></a>Goodlet KJ, Benhalima FZ, Nailor MD. A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy?. <i>Antimicrob Agents Chemother</i>. 2018;63(1):e02165-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/30397061/pubmed" id="30397061" target="_blank">30397061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34469706">
<a name="34469706"></a>Goss CH, Heltshe SL, West NE, et al; STOP2 Investigators. A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment. <i>Am J Respir Crit Care Med</i>. 2021;204(11):1295-1305. doi:10.1164/rccm.202102-0461OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/34469706/pubmed" id="34469706" target="_blank">34469706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6499344">
<a name="6499344"></a>Green TP, Mirkin BL, Peterson PK, et al. Tobramycin Serum Level Monitoring in Young Patients With Normal Renal Function. <i>Clin Pharmacokinet</i>. 1984;9(5):457-468.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/6499344/pubmed" id="6499344" target="_blank">6499344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8335520">
<a name="8335520"></a>Gudmundsson S, Einarsson S, Erlendsdottir H, Moffat J, Bayer W, Craig WA. The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model.<i> J Antimicrob Chemother.</i> 1993;31(suppl D):177-191. doi:10.1093/jac/31.suppl_d.177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/8335520/pubmed" id="8335520" target="_blank">8335520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.1">
<a name="Hooton.1"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18982422">
<a name="18982422"></a>Hagen I, Øymar K. Pharmacological Differences Between Once Daily and Twice Daily Gentamicin Dosage in Newborns With Suspected Sepsis. <i>Pharm World Sci</i>. 2009;31(1):18-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/18982422/pubmed" id="18982422" target="_blank">18982422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9590397">
<a name="9590397"></a>Hammett-Stabler CA, Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. <i>Clin Chem</i>. 1998;44(5):1129-1140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/9590397/pubmed" id="9590397" target="_blank">9590397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14647159">
<a name="14647159"></a>Hansen A, Forbes P, Arnold A, et al. Once-Daily Gentamicin Dosing for the Preterm and Term Newborn: Proposal for a Simple Regimen That Achieves Target Levels. <i>J Perinatol</i>. 2003;23(8):635-639.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/14647159/pubmed" id="14647159" target="_blank">14647159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37897526">
<a name="37897526"></a>Hari P, Meena J, Kumar M, et al. Evidence-based clinical practice guideline for management of urinary tract infection and primary vesicoureteric reflux. <i>Pediatr Nephrol</i>. Published online October 28, 2023. doi:10.1007/s00467-023-06173-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/37897526/pubmed" id="37897526" target="_blank">37897526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32507958">
<a name="32507958"></a>Hartman SJF, Orriëns LB, Zwaag SM, Poel T, de Hoop M, de Wildt SN. External validation of model-based dosing guidelines for vancomycin, gentamicin, and tobramycin in critically ill neonates and children: a pragmatic two-center study. <i>Paediatr Drugs</i>. 2020;22(4):433-444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/32507958/pubmed" id="32507958" target="_blank">32507958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3435131">
<a name="3435131"></a>Hassan E, Ober JD. Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients. <i>Antimicrob Agents Chemother</i>. 1987;31(11):1855-1858. doi:10.1128/aac.31.11.1855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/3435131/pubmed" id="3435131" target="_blank">3435131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30472292">
<a name="30472292"></a>Heffernan AJ, Sime FB, Lipman J, et al. Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: a systematic review. <i>Int J Antimicrob Agents.</i> 2019;53(3):234-245. doi:10.1016/j.ijantimicag.2018.11.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/30472292/pubmed" id="30472292" target="_blank">30472292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9408514">
<a name="9408514"></a>Hitt CM, Patel KB, Nicolau DP, et al. Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily. <i>Am J Health Syst Pharm</i>. 1997;54(23):2704-2708.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/9408514/pubmed" id="9408514" target="_blank">9408514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8119044">
<a name="8119044"></a>Hustinx WN, Hoepelman IM. Aminoglycoside Dosage Regimens. Is Once a Day Enough? <i>Clin Pharmacokinet</i>. 1993;25(6):427-432.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/8119044/pubmed" id="8119044" target="_blank">8119044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15825414">
<a name="15825414"></a>Jaffe G, Meyers BR, Hirschman SZ. Pharmacokinetics of Tobramycin in Patients With Stable Renal Impairment, Patients Undergoing Peritoneal Dialysis, and Patients on Chronic Hemodialysis. <i>Antimicro Agents Chemother</i>. 1974;5(6):611-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/15825414/pubmed" id="15825414" target="_blank">15825414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21407038">
<a name="21407038"></a>Jenh AM, Tamma PD, Milstone AM. Extended-interval aminoglycoside dosing in pediatrics. <i>Pediatr Infect Dis J</i>. 2011;30(4):338-339.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/21407038/pubmed" id="21407038" target="_blank">21407038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1102982">
<a name="1102982"></a>Kaiser AB, McGee ZA. Aminoglycoside therapy of gram-negative bacillary meningitis. <i>N Engl J Med</i>. 1975;293(24):1215-1220. doi:10.1056/NEJM197512112932401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/1102982/pubmed" id="1102982" target="_blank">1102982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanj.2020">
<a name="Kanj.2020"></a>Kanj SS, Sexton DJ. Principles of antimicrobial therapy of Pseudomonas aeruginosa infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10049277">
<a name="10049277"></a>Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. <i>Antimicrob Agents Chemother.</i> 1999;43(3):623-629.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/10049277/pubmed" id="10049277" target="_blank">10049277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3794874">
<a name="3794874"></a>Khan AJ, Kumar K, Evans HE. Single-dose gentamicin therapy of recurrent urinary tract infection in patients with normal urinary tracts. <i>J Pediatr</i>. 1987;110(1):131-135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/3794874/pubmed" id="3794874" target="_blank">3794874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klompas.1">
<a name="Klompas.1"></a>Klompas M. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12523459">
<a name="12523459"></a>Knoderer CA, Everett JA, Buss WF. Clinical Issues Surrounding Once-Daily Aminoglycoside Dosing in Children. <i>Pharmacotherapy</i>. 2003;23(1):44-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12523459/pubmed" id="12523459" target="_blank">12523459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25388408">
<a name="25388408"></a>König K, Lim A, Miller A, Saker S, Guy KJ, Barfield CP. Gentamicin trough levels using a simplified extended-interval dosing regimen in preterm and term newborns. <i>Eur J Pediatr</i>. 2015;174(5):669-673.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/25388408/pubmed" id="25388408" target="_blank">25388408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2762224">
<a name="2762224"></a>Koshida R, Nakashima E, Taniguchi N, Tsuji A, Benet LZ, Ichimura F. Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts. <i>Pharm Res</i>. 1989;6(6):486-491.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/2762224/pubmed" id="2762224" target="_blank">2762224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12083974">
<a name="12083974"></a>Kraus DM, Pai MP, Rodvold KA. Efficacy and Tolerability of Extended-Interval Aminoglycoside Administration in Pediatric Patients. <i>Paediatr Drugs</i>. 2002;4(7):469-484.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12083974/pubmed" id="12083974" target="_blank">12083974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675444">
<a name="9675444"></a>Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. <i>Clin Infect Dis</i>. 1998;27(1):23-27. doi:10.1086/514620<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/9675444/pubmed" id="9675444" target="_blank">9675444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27043949">
<a name="27043949"></a>LeBras M, Chow I, Mabasa VH, Ensom MH. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular aminoglycosides in adults. <i>Neurocrit Care</i>. 2016;25(3):492-507. doi:10.1007/s12028-016-0269-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/27043949/pubmed" id="27043949" target="_blank">27043949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leggett.1">
<a name="Leggett.1"></a>Leggett JE. Aminoglycosides. In: Bennett JE, Dolin R, Blaser MJ, eds. <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.</i> 8th ed. Elsevier Saunders; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20628102">
<a name="20628102"></a>Li PK, Szeto CC, Piraino B, et al; International Society for Peritoneal Dialysis. Peritoneal dialysis-related infections recommendations: 2010 update. <i>Perit Dial Int</i>. 2010;30(4):393-423. doi:10.3747/pdi.2010.00049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/20628102/pubmed" id="20628102" target="_blank">20628102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27282851">
<a name="27282851"></a>Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. <i>Perit Dial Int</i>. 2016;36(5):481-508. doi:10.3747/pdi.2016.00078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/27282851/pubmed" id="27282851" target="_blank">27282851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23571540">
<a name="23571540"></a>Louie A, Liu W, Fikes S, Brown D, Drusano GL. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia. <i>Antimicrob Agents Chemother.</i> 2013;57(6):2788-2792. doi:10.1128/AAC.02624-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/23571540/pubmed" id="23571540" target="_blank">23571540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MacDougall.1">
<a name="MacDougall.1"></a>MacDougall C, Chambers HF, eds. <i>Goodman &amp; Gilman's: The Pharmacological Basis of Therapeutics.</i> 12th ed. McGraw-Hill Global Education Holding; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987068">
<a name="29987068"></a>Mancini A, Todd L. Inconsistencies in ISPD peritonitis recommendations: 2016 update on prevention and treatment and the ISPD catheter-related infection recommendations: 2017 update. <i>Perit Dial Int</i>. 2018;38(4):309-310. doi:10.3747/pdi.2018.00026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/29987068/pubmed" id="29987068" target="_blank">29987068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16972966">
<a name="16972966"></a>Massie J, Cranswick N. Pharmacokinetic Profile of Once Daily Intravenous Tobramycin in Children With Cystic Fibrosis. <i>J Paediatr Child Health</i>. 2006;42(10):601-605.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/16972966/pubmed" id="16972966" target="_blank">16972966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23300401">
<a name="23300401"></a>Masvosva P, Buckingham SC, Einhaus S, Phelps SJ. Intraventricular and Intravenous Tobramycin with Ceftazidime for Ventriculitis Secondary to Pseudomonas aeruginosa. <i>J Pediatr Pharmacol Ther</i>. 2003;8(2):138-143. doi:10.5863/1551-6776-8.2.138<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/23300401/pubmed" id="23300401" target="_blank">23300401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6861633">
<a name="6861633"></a>Matzke GR, Burkle WS, Lucarotti RL. Gentamicin and tobramycin dosing guidelines: an evaluation. <i>Drug Intell Clin Pharm</i>. 1983;17(6):425-432. doi:10.1177/106002808301700604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/6861633/pubmed" id="6861633" target="_blank">6861633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3680577">
<a name="3680577"></a>Matzke GR, Jameson JJ, Halstenson CE. Gentamicin Disposition in Young and Elderly Patients With Various Degrees of Renal Function. <i>J Clin Pharmacol</i>. 1987;27(3):216-220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/3680577/pubmed" id="3680577" target="_blank">3680577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3743420">
<a name="3743420"></a>Mayer PR, Brown CH, Carter RA, et al. Intramuscular Tobramycin Pharmacokinetics in Geriatric Patients. <i>Drug Intell Clin Pharm</i>. 1986;20:611-615.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/3743420/pubmed" id="3743420" target="_blank">3743420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8568547">
<a name="8568547"></a>Mazzei T, Novelli A, De Lalla F, Mini E, Periti P. Tissue penetration and pulmonary disposition of tobramycin. <i>J Chemother.</i> 1995;7(4):363-370. doi:10.1179/joc.1995.7.4.363<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/8568547/pubmed" id="8568547" target="_blank">8568547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McCormack.1">
<a name="McCormack.1"></a>McCormack JP and Jewesson PJ. A Critical Re-evaluation of the “Therapeutic Range” of Aminoglycosides. <i>Clin Infect Dis</i>. 1992;14(1):320-339.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20180608">
<a name="20180608"></a>McDade EJ, Wagner JL, Moffett BS, et al. Once-Daily Gentamicin Dosing in Pediatric Patients Without Cystic Fibrosis. <i>Pharmacotherapy</i>. 2010;30(3):248-253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/20180608/pubmed" id="20180608" target="_blank">20180608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27848094">
<a name="27848094"></a>McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglycoside-induced nephrotoxicity in children. <i>Pediatr Nephrol</i>. 2017;32(11):2015-2025.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/27848094/pubmed" id="27848094" target="_blank">27848094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25465576">
<a name="25465576"></a>Miller MM, Burton ME, Johnson PN, Miller JL. "Once-daily" versus "extended-interval" administration of aminoglycosides in neonates: need for standard terminology. <i>Am J Health Syst Pharm</i>. 2014;71(24):2108-2109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/25465576/pubmed" id="25465576" target="_blank">25465576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moehring.2020">
<a name="Moehring.2020"></a>Moehring R, Anderson DJ. Gram-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29521784">
<a name="29521784"></a>Moffett BS, Kam C, Galati M, et al. The "ideal" body weight for pediatric gentamicin dosing in the era of obesity: a population pharmacokinetic analysis. <i>Ther Drug Monit</i>. 2018;40(3):322-329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/29521784/pubmed" id="29521784" target="_blank">29521784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23540878">
<a name="23540878"></a>Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. <i>Am J Respir Crit Care Med</i>. 2013;187(7):680-689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/23540878/pubmed" id="23540878" target="_blank">23540878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3540140">
<a name="3540140"></a>Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.<i> J Infect Dis.</i> 1987;155(1):93-99. doi:10.1093/infdis/155.1.93<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/3540140/pubmed" id="3540140" target="_blank">3540140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15964500">
<a name="15964500"></a>Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. Pharmacodynamics of tobramycin in patients with cystic fibrosis. <i>Diagn Microbiol Infect Dis.</i> 2005;52(2):123-127. doi:10.1016/j.diagmicrobio.2005.02.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/15964500/pubmed" id="15964500" target="_blank">15964500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20035611">
<a name="20035611"></a>Mueller EW, Boucher BA. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. <i>Surg Infect (Larchmt)</i>. 2009;10(6):563-570. doi:10.1089/sur.2007.080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/20035611/pubmed" id="20035611" target="_blank">20035611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nahata.1">
<a name="Nahata.1"></a>Nahata MC, Powell DA, Durrell DE, et al. Effect of Gestational Age and Birth Weight on Tobramycin Kinetics in Newborn Infants. <i>J Antimicrob Chemother</i>. 1984;14(1):59-65.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34264565">
<a name="34264565"></a>Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al; Contributors. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. <i>MMWR Recomm Rep</i>. 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/34264565/pubmed" id="34264565" target="_blank">34264565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24756148">
<a name="24756148"></a>Nezic L, Derungs A, Bruggisser M, Tschudin-Sutter S, Krähenbühl S, Haschke M. Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy. <i>Eur J Clin Pharmacol</i>. 2014;70(7):829-837. doi:10.1007/s00228-014-1680-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/24756148/pubmed" id="24756148" target="_blank">24756148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7793867">
<a name="7793867"></a>Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. <i>Antimicrob Agents Chemother</i>. 1995;39(3):650-655. doi: 10.1128/aac.39.3.650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/7793867/pubmed" id="7793867" target="_blank">7793867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30423035">
<a name="30423035"></a>Norris AH, Shrestha NK, Allison GM, et al. 2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy. <i>Clin Infect Dis</i>. 2019;68(1):e1-e35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/30423035/pubmed" id="30423035" target="_blank">30423035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11144309">
<a name="11144309"></a>Ohler KH, Menke JA, Fuller L. Use of Higher Dose Extended Interval Aminoglycosides in a Neonatal Intensive Care Unit. <i>Am J Perinatol</i>. 2000;17(6):285-290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/11144309/pubmed" id="11144309" target="_blank">11144309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22085385">
<a name="22085385"></a>Pagkalis S, Mantadakis E, Mavros MN, Ammari C, Falagas ME. Pharmacological considerations for the proper clinical use of aminoglycosides. <i>Drugs</i>. 2011;71(17):2277-2294. doi:10.2165/11597020-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/22085385/pubmed" id="22085385" target="_blank">22085385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17655508">
<a name="17655508"></a>Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. <i>Pharmacotherapy</i>. 2007;27(8):1081-1091. doi:10.1592/phco.27.8.1081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/17655508/pubmed" id="17655508" target="_blank">17655508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24268292">
<a name="24268292"></a>Pai MP, Rodvold KA. Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity. <i>Diagn Microbiol Infect Dis</i>. 2014;78(2):178-187. doi:10.1016/j.diagmicrobio.2013.10.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/24268292/pubmed" id="24268292" target="_blank">24268292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26942733">
<a name="26942733"></a>Panchaud A, Di Paolo ER, Koutsokera A, et al. Safety of drugs during pregnancy and breastfeeding in cystic fibrosis patients. <i>Respiration</i>. 2016;91(4):333-348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/26942733/pubmed" id="26942733" target="_blank">26942733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22768010">
<a name="22768010"></a>Prescott WA Jr. National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. <i>J Pediatr Pharmacol Ther</i>. 2011;16(4):262-269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/22768010/pubmed" id="22768010" target="_blank">22768010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20030477">
<a name="20030477"></a>Prescott WA Jr, Nagel JL. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. <i>Pharmacotherapy</i>. 2010;30(1):95-108. doi:10.1592/phco.30.1.95<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/20030477/pubmed" id="20030477" target="_blank">20030477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7667165">
<a name="7667165"></a>Preston SL, Briceland LL. Single Daily Dosing of Aminoglycosides. <i>Pharmacotherapy</i>. 1995;15(3):297-316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/7667165/pubmed" id="7667165" target="_blank">7667165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9878641">
<a name="9878641"></a>Ramsey BW, Pepe MS, Quan JM, et al; Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. <i>N Engl J Med</i>. 1999;340(1):23-30. doi:10.1056/NEJM199901073400104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/9878641/pubmed" id="9878641" target="_blank">9878641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19996339">
<a name="19996339"></a>Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. <i>Thorax</i>. 2010;65(4):286-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19996339/pubmed" id="19996339" target="_blank">19996339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19057371">
<a name="19057371"></a>Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. <i>Ther Drug Monit</i>. 2008;30(6):674-681. doi:10.1097/FTD.0b013e31818b6b2f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19057371/pubmed" id="19057371" target="_blank">19057371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15795653">
<a name="15795653"></a>Redmann S, Wainwright C, Stacey S, et al. Misleading High Tobramycin Plasma Concentrations Can Be Caused by Skin Contamination of Fingerprick Blood Following Inhalation of Nebulized Tobramycin (TOBI): A Short Report. <i>Ther Drug Monit</i>. 2005;27(2):205-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/15795653/pubmed" id="15795653" target="_blank">15795653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11724077">
<a name="11724077"></a>Robinson RF, Nahata MC. Safety of intravenous bolus administration of gentamicin in pediatric patients. <i>Ann Pharmacother</i>. 2001;35(11):1327-1331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/11724077/pubmed" id="11724077" target="_blank">11724077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21895037">
<a name="21895037"></a>Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. <i>Clin Pharmacokinet.</i> 2011;50(10):637-664. doi:10.2165/11594090-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/21895037/pubmed" id="21895037" target="_blank">21895037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27826154">
<a name="27826154"></a>Roy C, Gray C, Ruda L, Bell A, Bolt J. High-dose, extended-interval gentamicin and tobramycin for pediatric inpatients: a survey of Canadian hospital pharmacists. <i>Can J Hosp Pharm</i>. 2016;69(5):367-375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/27826154/pubmed" id="27826154" target="_blank">27826154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24599705">
<a name="24599705"></a>Rughoo L, Bourguignon L, Maire P, Ducher M. Study of relationship between volume of distribution and body weight application to amikacin. <i>Eur J Drug Metab Pharmacokinet</i>. 2014;39(2):87-91. doi:10.1007/s13318-013-0160-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/24599705/pubmed" id="24599705" target="_blank">24599705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10390201">
<a name="10390201"></a>Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. <i>Antimicrob Agents Chemother.</i> 1999;43(7):1549-1555.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/10390201/pubmed" id="10390201" target="_blank">10390201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3949634">
<a name="3949634"></a>Rybak MJ, Boike SC, Levine DP, Erickson SR. Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis. <i>J Antimicrob Chemother</i>. 1986;17(1):115-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/3949634/pubmed" id="3949634" target="_blank">3949634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27336007">
<a name="27336007"></a>Safi KH, Damiani JM, Sturza J, Nasr SZ. Extended-interval aminoglycoside use in cystic fibrosis exacerbation in children and young adults: a prospective quality improvement project. <i>Glob Pediatr Health</i>. 2016;3:2333794X16635464.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/27336007/pubmed" id="27336007" target="_blank">27336007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schmidt.2020">
<a name="Schmidt.2020"></a>Schmidt GA, Mandel J. Evaluation and management of suspected sepsis and septic shock in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397541">
<a name="19397541"></a>Serane TV, Zengeya S, Penford G, et al. Once Daily Dose Gentamicin in Neonates - Is Our Dosing Correct? <i>Acta Paediatr</i>. 2009;98(7):1100-1105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19397541/pubmed" id="19397541" target="_blank">19397541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simon.2020">
<a name="Simon.2020"></a>Simon RH. Cystic fibrosis: Management of pulmonary exacerbations. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11558860">
<a name="11558860"></a>Smith PF, Ballow CH, Booker BM, Forrest A, Schentag JJ. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. <i>Clin Ther</i>. 2001;23(8):1231-1244. doi:10.1016/s0149-2918(01)80103-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/11558860/pubmed" id="11558860" target="_blank">11558860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15708100">
<a name="15708100"></a>Smyth A, Tan KH, Hyman-Taylor P, et al. Once Versus Three-Times Daily Regimens of Tobramycin Treatment for Pulmonary Exacerbations of Cystic Fibrosis − The TOPIC Study: A Randomised Controlled Trial. <i>Lancet</i>. 2005;365(9459):573-578.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/15708100/pubmed" id="15708100" target="_blank">15708100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2010;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2764529">
<a name="2764529"></a>Southgate WM, DiPiro JT, Robertson AF. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. <i>Antimicrob Agents Chemother</i>. 1989;33(6):817-819.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/2764529/pubmed" id="2764529" target="_blank">2764529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stout.1">
<a name="Stout.1"></a>Stout J. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987069">
<a name="29987069"></a>Szeto CC, Li PK. Concerns regarding inconsistencies within and between ISPD recommendations for peritonitis and catheter-related infections-in reply. <i>Perit Dial Int</i>. 2018;38(4):311-312. doi:10.3747/pdi.2018.00046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/29987069/pubmed" id="29987069" target="_blank">29987069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33106864">
<a name="33106864"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance: Gram-Negative Bacterial Infections. <i>Clin Infect Dis</i>. Published online October 27, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/33106864/pubmed" id="33106864" target="_blank">33106864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Tobramycin 40 mg/mL and 10 mg/mL multiple-dose vial (tobramycin sulfate injection solution) [prescribing information]. Lake Forest, IL: Hospira; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxter.1">
<a name="Baxter.1"></a>Tobramycin 40 mg/mL multiple-dose vial (tobramycin sulfate injection solution) [prescribing information]. Lake Zurich, IL: Deerfield, IL: Baxter Healthcare Corporation; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.1">
<a name="Fresenius.1"></a>Tobramycin 1.2 g vial (tobramycin sulfate injection solution) [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA LLC; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19271781">
<a name="19271781"></a>Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. <i>Clin Pharmacokinet</i>. 2009;48(2):71-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19271781/pubmed" id="19271781" target="_blank">19271781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7726530">
<a name="7726530"></a>Traynor AM, Nafziger AN, Bertino JS Jr. Aminoglycoside dosing weight correction factors for patients of various body sizes. <i>Antimicrob Agents Chemother</i>. 1995;39(2):545-548. doi: 10.1128/aac.39.2.545<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/7726530/pubmed" id="7726530" target="_blank">7726530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy. <i>Clin Infect Dis</i>. 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice Guidelines for the Management of Bacterial Meningitis. <i>Clin Infect Dis</i>. 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis [published online February 14, 2017]. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-UKCF.1">
<a name="UKCF.1"></a>UK Cystic Fibrosis Trust Antibiotic Working Group. Antibiotic treatment for cystic fibrosis – 3rd edition. May 2009. Available at https://www.cysticfibrosis.org.uk/~/media/documents/the-work-we-do/care/consensus-docs-with-new-address/anitbiotic-treatment.ashx?la=en
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1107297">
<a name="1107297"></a>Uwaydah M, Bibi S, Salman S. Therapeutic Efficacy of Tobramycin - A Clinical and Laboratory Evaluation. <i>J Antimicrob Chemother</i>. 1975;1(4):429-437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/1107297/pubmed" id="1107297" target="_blank">1107297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25766737">
<a name="25766737"></a>Valitalo PA, van den Anker JN, Allegaert K, et al. Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. <i>J Antimicrob Chemother</i>. 2015;70(7):2074-2077.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/25766737/pubmed" id="25766737" target="_blank">25766737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29358294">
<a name="29358294"></a>van Donge T, Pfister M, Bielicki J, et al. Quantitative Analysis of Gentamicin Exposure in Neonates and Infants Calls into Question Its Current Dosing Recommendations. <i>Antimicrob Agents Chemother</i>. 2018;62(4):e02004-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/29358294/pubmed" id="29358294" target="_blank">29358294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26836810">
<a name="26836810"></a>van Maarseveen EM, Sprij A, Touw DJ. Extended-interval dosing of gentamicin aiming for a drug-free period in neonates: a prospective cohort study. <i>Ther Drug Monit</i>. 2016;38(3):402-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/26836810/pubmed" id="26836810" target="_blank">26836810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19330772">
<a name="19330772"></a>Van Meter DJ, Corriveau M, Ahern JW, et al. A Survey of Once-Daily Dosage Tobramycin Therapy in Patients With Cystic Fibrosis. <i>Pediatr Pulmonol.</i> 2009;44(4):325-329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/19330772/pubmed" id="19330772" target="_blank">19330772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Varese.1">
<a name="Varese.1"></a>Varese LA, Grazioli F, Viretto A, Antoniola P. Single-dose (bolus) therapy with gentamicin in management of urinary tract infection. <i>International Journal of Pediatric Nephrology</i>. 1980;1(2):104-105.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update. <i>Perit Dial Int</i>. 2012;(32)(suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23055867">
<a name="23055867"></a>Wassil SK, Fox KM, White JW. Once daily dosing of aminoglycosides in pediatric cystic fibrosis patients: a review of the literature. <i>J Pediatr Pharmacol Ther</i>. 2008;13(2):68-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/23055867/pubmed" id="23055867" target="_blank">23055867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12951354">
<a name="12951354"></a>Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. <i>J Antimicrob Chemother</i>. 2003;52(4):668-674. doi:10.1093/jac/dkg403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/12951354/pubmed" id="12951354" target="_blank">12951354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27453702">
<a name="27453702"></a>Zobell JT, Epps K, Kittell F, et al. Tobramycin and beta-lactam antibiotic use in cystic fibrosis exacerbations: a pharmacist approach. <i>J Pediatr Pharmacol Ther</i>. 2016;21(3):239-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-systemic-pediatric-drug-information/abstract-text/27453702/pubmed" id="27453702" target="_blank">27453702</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 105135 Version 210.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
